A growing amount of evidence identifies PGC-1α as a potential therapeutic target in neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). The gene discussed is PPARGC1A; the disease is early-onset autosomal dominant Alzheimer disease.